Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus.
We have examined the urinary excretion of stable immunoreactive eicosanoids in 23 female patients with systemic lupus erythematosus (SLE), 16 patients with chronic glomerular disease (CGD), and 20 healthy women. SLE patients had significantly higher urinary thromboxane B2 (TXB2) and prostaglandin (PG) E2 excretion and significantly lower 6-keto-PGF1 alpha than did healthy women. In contrast, CGD patients only differed from controls for having reduced 6-keto-PGF1 alpha excretion. The group of SLE patients with active renal lesions differed significantly from the group with inactive lesions for having a lower creatinine clearance and urinary 6-keto-PGF1 alpha and higher urinary TXB2. Higher urinary TXB2 excretion was associated with comparable platelet TXB2 production in whole blood, undetectable TXB2 in peripheral venous blood, and unchanged urinary excretion of 2,3-dinor-TXB2. A significant inverse correlation was found between urinary TXB2 and creatinine clearance rate (CCr). In contrast, the urinary excretion of 6-keto-PGF1 alpha showed a significant linear correlation with both CCr and para-aminohippurate clearance rate (CPAH). In four SLE and seven CGD patients, inhibition of renal cyclooxygenase activity by ibuprofen was associated with a significant reduction in urinary 6-keto-PGF1 alpha and TXB2 and in both CCr and CPAH. However, the average decrease in both clearances was 50% lower in SLE patients than in CGD patients, when fractionated by the reduction in urinary 6-keto-PGF1 alpha or PGE2 excretion. We conclude that the intrarenal synthesis of PGI2 and TXA2 is specifically altered in SLE. Such biochemical alterations are associated with changes in glomerular hemodynamics and may play a role in the progression of SLE nephropathy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000378:metabolism; D002908:Chronic Disease; D015237:Dinoprost; D015232:Dinoprostone; D011464:Epoprostenol / Q000096:biosynthesis*; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D005921:Glomerulonephritis / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism / Q000503:physiopathology*; D007677:Kidney Function Tests; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000378:metabolism* / Q000652:urine; D008875:Middle Aged; D011458:Prostaglandins E / Q000652:urine; D011460:Prostaglandins F / Q000652:urine; D011863:Radioimmunoassay; D013928:Thromboxane A2 / Q000096:biosynthesis*; D013929:Thromboxane B2 / Q000652:urine
D011458:Prostaglandins E; D011460:Prostaglandins F; D013929:Thromboxane B2; D013928:Thromboxane A2; D015237:Dinoprost; D011464:Epoprostenol; D015232:Dinoprostone; D007052:Ibuprofen